SynthesisJournal of neurology2025
Sex differences in antiseizure medications response in people with epilepsy: a systematic review.
Synthesis in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAs a part of a wider project aimed to assess sex-related differences in adverse effects and efficacy of antiseizure medications (ASMs), we performed a systematic review focusing on differences in response to ASMs between males and females with epilepsy.
methodWe conducted a comprehensive literature search in the PubMed database. The search was conducted without restriction on publication date, and all results up to September 2022 were included. We included all the articles written in English, Italian, Spanish, or French language evaluating the response to ASMs in people with epilepsy (PWE), with specific mention of the two sexes. The Newcastle-Ottawa Scale and the Jadad Scale were used to assess study quality.
resultsA total of 1778 studies were identified. Of these, 60 studies searched for sex differences and among those, 46 (76%) did not identify statistically significant differences. Only 14 studies (23%) identified sex as a statistically significant variable in ASM efficacy. Among those, a greater number of studies reported higher rates of seizure reduction or seizure freedom in males using different ASMs, with 9 studies vs 5 in which drug response was higher in males.
conclusionsOur study has identified male sex as a predictor of drug response in epilepsy in the majority of studies that found sex differences. However, the scarcity of data found in the literature highlights the need for a systematic evaluation of sex as a variable influencing the response to medications in clinical research.
Indexed as
Identifiers
40679631What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.